Mieke Bus

1 15 Reference list 1. Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015; 68(5): 868-79. 2. Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010; 116(12): 2967-73. 3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEnglJMed 2004; 351(13): 1296-305. 4. Xylinas E, Rink M, Margulis V, et al. Impact of renal function on eligibility for chemo- therapy and survival in patients who have undergone radical nephro-ureterectomy. BJUInt 2013; 112(4): 453-61. 5. Kaag MG, O’Malley RL, O’Malley P, et al. Changes in renal function following nephroure- terectomy may affect the use of perioperative chemotherapy. EurUrol 2010; 58(4): 581-7. 6. Ristau BT, Tomaszewski JJ, Ost MC. Upper tract urothelial carcinoma: current treatment and outcomes. Urology 2012; 79(4): 749-56. 7. Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology 2012; 79(3): 615-9. 8. Cauberg EC, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJ, de Reijke TM. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accu- racy, and future applications. EurUrol 2009; 56(2): 287-96. 9. Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: consid- erations and perspectives. JUrol 2012; 188(2): 361-8.